Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Orexin: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| SLEEP-WAKE CYCLE | regulates | entity | 0.90 |
| Sleep-Wake Cycle | regulates | process | 0.90 |
| OBSTRUCTIVE SLEEP APNEA SYNDROME | biomarker_for | entity | 0.85 |
| OSAS | biomarker_for | disease | 0.85 |
| Daytime Sleepiness | modulates | phenotype | 0.80 |
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Circadian Glymphatic Entrainment via Targeted Orexin Recepto | 0.841 | neurodegeneration | Perivascular spaces and glymphatic clear |
| Night-phase orexin receptor antagonism rescues AD by restori | 0.733 | neurodegeneration | Orexin-A manipulation in AD cognition an |
| Orexin-Microglia Modulation Therapy | 0.707 | neurodegeneration | Sleep disruption as cause and consequenc |
| Excess orexin-A worsens AD cognition through wake-driven amy | 0.686 | neurodegeneration | Orexin-A manipulation in AD cognition an |
| Daytime orexin tone preserves synaptic plasticity in prodrom | 0.625 | neurodegeneration | Orexin-A manipulation in AD cognition an |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Circadian Dysfunction as Driver of Neurodegeneration | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep Disruption and Alzheimer's Disease — mechanism and intervention | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Respiratory Network Interaction in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Brainstem Circuit Modulation for PSP | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Combination Therapy Sequencing in Parkinson's Disease | validation | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $2,280,000 |
| Non-Dopaminergic Neurotransmitter Degeneration in PD - Experiment Desi | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Low Rates of Gastrointestinal and Non-Gastrointestinal Complications for Screeni [PMID:29031502] | Wang L, Mannalithara A, Singh G, Ladabau | Gastroenterology | 2018 | 1 |
| Als and Ftd: Insights into the disease mechanisms and therapeutic targets. [PMID:29031901] | Liscic RM | Eur J Pharmacol | 2017 | 1 |
| Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling [PMID:28336668] | Castellano BM, Thelen AM, Moldavski O, F | Science | 2017 | 1 |
| Defining the consequences of genetic variation on a proteome-wide scale. [PMID:27309819] | Chick JM, Munger SC, Simecek P, Huttlin | Nature | 2016 | 1 |
| A comparative examination of thrombocyte/platelet immunity. [PMID:25448707] | F Ferdous, T R Scott | Immunology letters | 2015 | 1 |
| A three-dimensional human neural cell culture model of Alzheimer's disease. [PMID:25307057] | Choi SH, Kim YH, Hebisch M, Sliwinski C, | Nature | 2014 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Dual hypocretin receptor antagonists enhance sleep and nursing behavior in lacta [PMID:41870530] | ["Rivas M", "Pe\u00f1a F", "Prota C", "C | Psychopharmacology | 2026 | 0 |
| Prioritizing Neuroactive Ligands Using Motif-Guided Virtual Discovery and Zebraf [PMID:41648545] | ["Ginsparg A", "Martinez J", "Patel I", | bioRxiv : the preprint server | 2026 | 0 |
| Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in [PMID:41359331] | ["Lammers G", "Plazzi G", "Mignot E", "P | JAMA neurology | 2026 | 0 |
| Association between genetic polymorphisms in circadian cycle genes ( [PMID:41787892] | ["Alves R", "da Cunha L", "Albuquerque A | Chronobiology international | 2026 | 0 |
| Sex-Specific Effects of Hypocretin Receptor Signaling in Corticotropin-Releasing [PMID:41256182] | ["Ma Y", "Sardar H", "Benabou M", "Yu A" | Biological psychiatry global o | 2026 | 0 |
| Estimation of the Orexin Receptor Occupancy From Human Plasma Pharmacokinetics o [PMID:41622624] | ["Kamigaso S", "Konno Y", "Hikichi H", " | Pharmacology research & perspe | 2026 | 0 |
| Social defeat stress responses in the stress alternative model are dependent on [PMID:41834039] | ["Yaeger J", "John M", "Ledesma L", "Gre | Biology of sex differences | 2026 | 0 |
| Signal transduction, dimerization, and therapeutic targeting of Orexin and recep [PMID:41383480] | Zhang S, Wang P, Ji B, Shao Y, Hou S et | Front Pharmacol | 2025 | 0 |
| Acute carbamoylated erythropoietin reduces social stress-induced anxiety and dep [PMID:40514007] | Yaeger JDW, John MM, Ledesma LJ, Krupp K | Neuropharmacology | 2025 | 0 |
| Bioinformatic analysis of neuropeptide related genes in patients diagnosed with [PMID:39437604] | Yay F, Ayan D | Comput Biol Med | 2024 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Orexin in their description or question text
No additional research found